

# **Proposed Recommendations 2015-16 Influenza Season**

**Lisa Grohskopf, MD  
Influenza Division, CDC**

**Advisory Committee on Immunization Practices  
February 25, 2015**



# Influenza Work Group

## **ACIP Members**

Ruth Karron (Chair)  
Ed Belongia  
Lee Harrison

## ***Ex Officio* Members**

Melisse Baylor (FDA)  
David Cho (FDA)  
Bruce Gellin (HHS)  
Lucia Lee (FDA)  
Cynthia Noletti (FDA)  
Rachelle Salomon (NIH)

## **Consultants**

Jeff Duchin  
Wendy Keitel

## **Liaison Representatives**

Kevin Ault (ACOG)  
Hank Bernstein (AAP)  
Jan Englund (PIDS)  
Sandra Fryhofer (ACP; AMA)  
Marie-Michèle Léger (AAPA)  
Susan Lett (CSTE)  
Jamie Loehr (AAFP)  
Kathy Neuzil (IDSA)  
Lisa Ipp (SAHM)  
William Schaffner (NFID)  
Rob Schechter (AIM)  
Ken Schmader (AGS)  
Nadine Sicard (NACI)  
Patsy Stinchfield (NAPNAP)  
Tamara Sheffield (AHIP)  
Matthew Zahn (NACCHO)

## **CDC Lead**

Lisa Grohskopf (CDC/NCIRD,  
Influenza Division)

# Acknowledgements

Alicia Fry  
Brendan Flannery  
Jessie Clippard  
Swathi Thacker  
Sarah Spencer  
US Influenza Vaccine Efficacy  
Network

Lyn Finelli  
Tiffany D'Mello  
Lynnette Brammer  
Lenee Blanton  
Krista Kniss  
Rosaline Dhara  
Desiree Mustaquim  
Michelle Leon  
Andrea Steffens  
Craig Steffens  
Ashley Fowlkes  
Michael Jhung

Natalie Kramer  
Sophie Smith

Rebecca Garten  
Angie Cost

Joe Bresee  
Carolyn Bridges  
Karen Broder  
Jessie Clippard  
Angie Cost  
Nancy Cox  
Frank DeStefano  
Sandra Dos Santos Chaves  
Lyn Finelli  
Brendan Flannery  
Alicia Fry  
Paul Gargiullo

Sam Graitcer  
Penina Haber  
Erin Kennedy  
Andrew Kroger  
Jeanne Santoli  
David Shay  
Tom Shimabukuro  
Jerry Tokars  
Tim Uyeki  
  
Leslie Sokolow  
Sonja Olsen

# Persons Recommended for Vaccination

## Reiteration of core recommendation:

Annual influenza vaccination is recommended for all persons 6 months of age and older.

- A licensed, age-appropriate influenza vaccine should be used
- Recommendations for different vaccine types and specific populations discussed in the ACIP statement

# Use of LAIV for Children 2 through 8 Years Of Age

## Current language (2014-15):

- ❑ When immediately available, LAIV should be used for healthy children aged 2 through 8 years who have no contraindications or precautions.

## Proposed revision (2015-16):

- ❑ For healthy children aged 2 through 8 years who have no contraindications or precautions, either LAIV or IIV is an appropriate option. No preference is expressed for LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is appropriate.

## LAIV Recommendations (Proposed)—1

- All persons aged  $\geq 6$  months should receive influenza vaccine annually. Influenza vaccination should not be delayed to procure a specific vaccine preparation if an appropriate one is already available.
- (Proposed revision) For healthy children aged 2 through 8 years who have no contraindications or precautions, either LAIV or IIV is an appropriate option. No preference is expressed for LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is appropriate. An age-appropriate formulation of vaccine should be used.

## LAIV Recommendations (Proposed)—2

- LAIV should not be used for the following persons
  - Persons aged <2 years or >49 years
  - Children aged 2 through 17 years who are receiving aspirin or aspirin-containing products;
  - Persons who have experienced severe allergic reactions to the vaccine or any of its components, or to a previous dose of any influenza vaccine;
  - Pregnant women;
  - Immunosuppressed persons;
  - Persons with a history of egg allergy;
  - Children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma within the last 12 months
  - Persons who have taken influenza antiviral medications within the previous 48 hours.

## LAIV Recommendations (Proposed)—3

- In addition to the groups for whom LAIV is not recommended above, the "Warnings and Precautions" section of the LAIV package insert indicates that persons of any age with asthma might be at increased risk for wheezing after administration of LAIV, and notes that the safety of LAIV in persons with other underlying medical conditions that might predispose them to complications after wild-type influenza infection (e.g., chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus]) has not been established. These conditions, in addition to asthma in persons aged  $\geq 5$  years, should be considered precautions for the use of LAIV.

## LAIV Recommendations (Proposed)—4

- Persons who care for severely immunosuppressed persons who require a protective environment should not receive LAIV, or should avoid contact with such persons for 7 days after receipt, given the theoretical risk for transmission of the live attenuated vaccine virus.

# Thank You

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: [cdcinfo@cdc.gov](mailto:cdcinfo@cdc.gov) Web: [www.cdc.gov](http://www.cdc.gov)

